|Other Names||Cytidine deaminase, Cytidine aminohydrolase, CDA, CDD|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2868c was selected from the Center region of human CDA. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.|
|Tissue Location||Highly expressed in granulocytes while expression is very low in fibroblasts, chondrocytes, monocytes, and T- as well as B-cell lines|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CDA forms a homotetramer that catalyzes the irreversible hydrolytic deamination of cytidine and deoxycytidine to uridine and deoxyuridine, respectively. This protein is one of several deaminases responsible for maintaining the cellular pyrimidine pool. Mutations in the CDA gene are associated with decreased sensitivity to the cytosine nucleoside analogue cytosine arabinoside used in the treatment of certain childhood leukemias.
Laliberte J., Momparler R.L.Cancer Res. 54:5401-5407(1994)Demontis S., Terao M.Biochim. Biophys. Acta 1443:323-333(1998) Kuhn K., Bertling W.M., Emmrich F.Biochem. Biophys. Res. Commun. 190:1-7(1993)
If you have any additional inquiries please email technical services at email@example.com.